

Quantitation of immunoblots in Figure 1A by ImageJ.



Quantitation of immunoblots in Figure 2A by ImageJ.



Quantitation of immunoblots in Figure 3A by ImageJ.



Quantitation of immunoblots in Figure 3D by ImageJ.



Quantitation of immunoblots in Figure 4A by ImageJ.





Quantitation of immunoblots in Figure 4D by ImageJ.





Quantitation of immunoblots in Figure 5A by ImageJ.

Figure W8



Immunoblot analysis shows that Usp9x KD in human PDAC, mutant Kras cell line MIAPACA2 reduces Mcl-1 expression levels whereas Usp9x KD in the mouse mutant Kras cell line 8041 increases Mcl-1 levels.

Figure W9



MTT assay shows that Usp9x KD in PANC1 cells enhances their growth rate but has no effect on the growth of BxPC3 cells. Control and Usp9xKD PANC1 and BxPC3 cells were grown in 96 well culture clusters in triplicates and the samples were subjected to MTT analysis at day 0, 1, 2 and 3. Error bars (S.D.) are enclosed within the symbol.

Figure W10

A. 8041-Xenograft:



A. Survival plot showing the weight of vehicle and G9 treated mice throughout the treatment period for 8041-tumor bearing mice.

B. MIAPACA2-Xenograft:



A. Survival plot of mouse weight of vehicle and G9 treated MIAPCA2 tumors throughout the treatment period.

Figure W11



MTT assay shows that Usp9X KD in 8041 cells does not alter the proliferation rate of these cells as compared to scrambled control cells. 8041-Control, 8041-Usp9xKD1 and 8041-Usp9xKD2 cells were plated in triplicates in 96 well culture clusters and assessed for growth in monolayer at day 0, 1, 2, 3 and 4 by MTT assay. The average of triplicate assays is shown. Error bars (S.D.) are enclosed within the symbol.